March 2, 2022 4:49pm

Share pricing remains very fluid, which means that back and forth is likely to continue

Pre-open indications: 9 Hits, 2 Miss and 1 Pimp/Pump/Promote

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Daily perspective …

 

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +596.40 points (+1.79%); the S&P closed UP +80.28 points (+1.86%) while the Nasdaq closed UP +219.56 points (+1.62%)

 

Henry’omics:

Investors remained on edge although …

Indexes rose on Wednesday despite a continued surge in oil prices surged amid the intensifying conflict between Russia and Ukraine.

Fed Chair Powell said that the central bank still plans on raising interest rates despite the “highly uncertain” economic effects of the war in Ukraine. “The bottom line is we will proceed but we will proceed carefully as we learn more about the implications of the Ukraine war,” Powell told the House Financial Services Committee.

Economic Data Docket: ADP private payrolls report; private companies in the U.S. added 475,000 jobs in February. The firm also revised its January numbers upward. Economists polled were expecting 400,000.

 

RegMed Investors’ (RMi) pre-open: “after a sell-off, a pop and a profit mode? The market remains headline driven; I’m seeing some positives even under the shade of tanks rolling.” … https://www.regmedinvestors.com/articles/12323

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Wednesday opened negative at 14 up/18 downs, 2 flats and 1 acquired, flipped positive at the mid-day at 19/15 and 1 acquired, ending with a positive close of 20/15, 1 flat and 1 acquired;

 

Pre-open Indications: 9 Hits < Homology Medicine (FIXX +$0.04), Alnylam Pharmaceuticals (ALNY +$0.69), Ionis Pharmaceuticals (IONS -$0.93), CRISPR Therapeutics (CRSP +$1.34), Global Blood Therapeutics (GBT -$0.93), Sangamo Therapeutics (SGMO -$0.04), ReNeuron (RENE.L -$1.00), Intellia Therapeutics (NTLA +$4.54), Pluristem (PSTI +$0.13)> 2 Miss < Applied Genetic Technologies (AGTC -$0.09), Editas Medicine (EDIT -$0.34), > 1 Pimp/Pump/Promote < Biostage (OTCQB: BSTG +$0.34>

 

UC Berkeley loses CRISPR patent case, invalidating licenses it granted gene-editing companies https://www.regmedinvestors.com/articles/12320 - added more commentary

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  …

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works on Wednesday as 649 shares appeared pushing the share price +$0.34 after Tuesday as 3,271 shares appear raising the share price +$0.59 to have it close -$0.04 with an additional 278 shares traded after Monday with 687 shares traded +$0.37 just before the close

 

Key Metrics:

  • Wednesday - Sector volume was LOW with 3 of the 20-upside having higher than the 3-month average volume with LOW volume of 0 of 13-downside having higher than the 3-month average volume

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday   the IBB closed up +0.53% and XBI closed up +0.25%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -2.57 points or -7.74% at 30.74

 

Jumping with share pricing momentum (10 of 20):

  • Intellia Therapeutics (NTLA +$4.54 after Tuesday’s -$19.00),
  • Regenxbio (RGNX +$2.67 after Tuesday’s +$0.24),
  • Vericel (VCEL +$2.63 after Tuesday’s -$0.42),
  • CRISPR Therapeutics (CRSP +$1.34 after Tuesday’s -$3.93),
  • Alnylam Pharmaceuticals (ALNY +$0.69 after Tuesday’s +$4.66),
  • uniQure NV (QURE +$0.64 after Tuesday’s +$0.49),
  • Fate Therapeutics (FATE +$0.55 after Tuesday’s -$0.13),
  • BioLife Solutions (BLFS +$0.44 after Tuesday’s +$0.21),
  • AxoGen (AXGN +$0.42 after Tuesday’s -$0.28),
  • Biostage (BSTG +$0.34),

Hammered in today’s market (13 of 13):

  • ReNeuron (RENE.L -$1.00 after Tuesday’s -$1.00),
  • Global Blood Therapeutics (GBT -$0.93 after Tuesday’s -$0.33),
  • Ionis Pharmaceuticals (IONS -$0.93 after Tuesday’s +$0.70),
  • Editas Medicine (EDIT -$0.34 after Tuesday’s +$0.37),
  • Cellectis SA (CLLS -$0.18),
  • Applied Genetic Technologies (AGTC -$0.09),
  • bluebird bio (BLUE -$0.08 after Tuesday’s -$0.42),
  • Athersys (ATHX -$0.045),
  • Sangamo Therapeutics (SGMO -$0.04),
  • Homology Medicine (FIXX +$0.06),
  • Voyager Therapeutics (VYGR -$0.02),
  • Solid Biosciences (SLDB -$0.009),
  • Adverum Biotechnologies (ADVM -$0.005),

Closing:

1 – Mesoblast (MESO) and 1 - Stemline Therapeutics (STML) – acquired

 

March, Q1/2022:

  • Wednesday closed positive with 20 incliners, 13 decliners, 1 flat and 1 acquired
  • Tuesday closed negative with 15 incliners, 18 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: The cell and gene therapy sector is hanging tough after a turbulent February.

Even Q4 and FY21 earnings have not stimulated a downward trend.

A good quote, “Inflation is running rampant. Profit margins are under attack. Vladimir Putin is playing terror to the world. And yet, there are markets fixated on rate hike comments from one of the most powerful people in the financial industry in Powell.” <Yahoo Finance>

Markets ended sharply lower on Tuesday, with cell and gene therapy stocks feeling the pain after three (3) up sessions as the Russia-Ukraine crisis deepened and stirred agita among investors.

Gene editing investors are still swimming up and down stream with Editas Medicine (EDIT -$0.35), Intellia Therapeutics (NTLA +$4.76) and CRISPR Therapeutics (CRSP +1.64) trading, post the U.S. patent office ruled the Broad Institute patent was “more” valid than UC Berkely. (Read more … https://www.regmedinvestors.com/articles/12320)

Remember the adage, “It takes two to make a market"; that’s sellers and buyers.

I am always anticipating the risks – as my careers focus has been “warning analysis”.

Q4 and end-of-year earnings are gaming than even I thought.

Earnings’ reporting coming:

·         Athersys (ATHX), Tuesday, 3/15

·         Cellectis SA (CLLS) Thursday, 3/22

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.